Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity
- PMID: 17197522
- DOI: 10.1167/iovs.06-0283
Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity
Abstract
Purpose: To estimate the potential public health impact of treatment with new medications intended to preserve vision in patients with neovascular age-related macular degeneration (AMD).
Methods: A Markov model was used to simulate the natural history of AMD over the lifetime of patients with diagnosed neovascular AMD from clinical trials and epidemiologic surveys. It applied to a cohort of patients aged 75 years, with newly diagnosed neovascular AMD in one eye, whose visual acuity was 0.7 logMAR. Probabilities were calculated for the risk of AMD in the remaining eye and for premature mortality. Results of the model were expressed as the duration of low vision (worse eye VA>1.0 and better eye VA>0.7 logMAR) and blindness (bilateral VA >1.0 logMAR). Health consequences of blindness and low vision were estimated for depression, hip fractures, institutionalization, and life expectancy.
Results: For AMD patients with a 50% probability of VA >1.0 logMAR at 1 year, in one eye, the probability of lifetime bilateral blindness was >47%. The patients would live approximately 7 years with monocular vision >1.0 logMAR and an additional 4 years with bilateral blindness and a >15% probability of depression due to AMD. Life expectancy was decreased by approximately 2 years, >90/1000 patients would sustain a new hip fracture, and 1.5% of the patients would require institutional care for visual impairment due to AMD. To achieve a defined public health outcome (visual impairment and consequent comorbidity), it was necessary for the VA effectiveness of new treatments to increase in parallel with disease severity.
Conclusions: Comorbidity related to visual impairment contributes significantly to the public health impact of AMD. Aggressive lesions need highly effective treatments. Models may be used to compare the public health impact of placebo-controlled clinical trial results.
Similar articles
-
Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity.Optom Vis Sci. 2006 Mar;83(3):178-89. doi: 10.1097/01.opx.0000204510.08026.7f. Optom Vis Sci. 2006. PMID: 16534460 Review.
-
Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.Surv Ophthalmol. 2005 May-Jun;50(3):263-73. doi: 10.1016/j.survophthal.2005.02.007. Surv Ophthalmol. 2005. PMID: 15850815 Review.
-
Vision-related quality of life in patients suffering from age-related macular degeneration.Am J Ophthalmol. 2005 Feb;139(2):271-9. doi: 10.1016/j.ajo.2004.09.028. Am J Ophthalmol. 2005. PMID: 15733988
-
Vision-related quality of life in patients with bilateral severe age-related macular degeneration.Ophthalmology. 2005 Jan;112(1):152-8. doi: 10.1016/j.ophtha.2004.06.036. Ophthalmology. 2005. PMID: 15629836
-
Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.Am J Ophthalmol. 2004 Jul;138(1):91-108. doi: 10.1016/j.ajo.2004.02.011. Am J Ophthalmol. 2004. PMID: 15234287 Clinical Trial.
Cited by
-
Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019.Front Public Health. 2023 Apr 17;11:1138428. doi: 10.3389/fpubh.2023.1138428. eCollection 2023. Front Public Health. 2023. PMID: 37265519 Free PMC article.
-
Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.Sci Rep. 2019 Feb 22;9(1):2614. doi: 10.1038/s41598-019-38919-7. Sci Rep. 2019. PMID: 30796269 Free PMC article.
-
Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):651-663. doi: 10.1007/s00417-018-3917-9. Epub 2018 Feb 10. Graefes Arch Clin Exp Ophthalmol. 2018. PMID: 29429131
-
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration.BMC Ophthalmol. 2017 Oct 10;17(1):189. doi: 10.1186/s12886-017-0586-0. BMC Ophthalmol. 2017. PMID: 29017506 Free PMC article.
-
Association of Htra1 gene polymorphisms with the risk of developing AMD in Iranian population.Rep Biochem Mol Biol. 2015 Oct;4(1):43-9. Rep Biochem Mol Biol. 2015. PMID: 26989749 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical